Safety and Efficacy of Mepolizumab during Pregnancy and Postpartum
DOI:
https://doi.org/10.20344/amp.24222Keywords:
Anti-Asthmatic Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Asthma/drug therapy, Postpartum Period/drug effects, PregnancyAbstract
n/a.
Downloads
References
Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56:2000151. DOI: https://doi.org/10.1183/13993003.00151-2020
European Medicines Agency. Nucala: sumary of product characteristics (SmPC). [cited 2026 Jan 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf.
Vittorakis SK, Giannakopoulou G, Samitas K, Zervas E. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. Respir Med Case Rep. 2022;41:101785. DOI: https://doi.org/10.1016/j.rmcr.2022.101785
Jang W, Jo H, Park J, Kim S, Cho H, Jeong YD, et al. Use of biologics to treat asthma during pregnancy and adverse events in pregnant women and newborns: a global pharmacovigilance analysis. Int Arch Allergy Immunol. 2025;186:875-88. DOI: https://doi.org/10.1159/000543490
European Medicines Agency. The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy (200870 NPSS (Nucala Pregnancy Surveillance Study)). [cited 2025 Aug 16]. Available from: https://catalogues.ema.europa.eu/node/2613/administrative-details.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
